AHCYL2 is altered in 0.05% of all cancers with astrocytoma, low-grade glioma, NOS, pancreatic adenocarcinoma, pilocytic astrocytoma, and thyroid gland papillary carcinoma having the greatest prevalence of alterations .
The most common alterations in AHCYL2 are AHCYL2-BRAF Fusion (0.14%) and AHCYL2-SMO Fusion (0.01%) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.